 This was an open-label Phase III, multicenter, multinational, randomized, 3-arm study designed to evaluate the efficacy and safety of bevacizumab in combination with either intermittent fluorouracilleucovorin with oxaliplatin FOLFOX4 or capecitabine plus oxaliplatin XELOX versus FOLFOX4 regimen alone, as adjuvant chemotherapy in colon carcinoma. 